<DOC>
	<DOC>NCT01717924</DOC>
	<brief_summary>The ADCI 002 trial is a large multicenter phase II-III prospective randomized controlled trial comparing primary surgery versus primary chemotherapy followed by surgery in patients with a resectable signet ring cell gastric adenocarcinoma</brief_summary>
	<brief_title>Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>adenocarcinoma of the stomach or the oesogastric junction of type III of Siewert classification,histologically proven with the presence of signet ring cells (according to WHO 2000 classification) or diffuse form (according to Lauren classification) on pretherapeutic biopsies tumoural stage IB, II or III (according to UICCAJCC 2009) patient judged resectable in a curative intent on inclusion absence of distant metastasis absence of peritoneal carcinomatosis during pretreatment explorative laparoscopy WHO performance status 2 or less age over 18 or under 80 years weight loss at the time of inclusion &lt; 15% neutrophilic polynuclears more than 1500/mm3 platelets more than 100000/mm3 creatinine clearance more than 50 ml/min serumalbumin more than 30 gram/l bilirubin less than 1,5 normal prothrombin rate over 80% absence of prior treatment with chemotherapy or radiotherapy for gastric cancer absence of kniwn child B or C cirrhosis left ventricular ejection fraction more than 50% before epirubicin treatment extension checkup performed within 4 weeks of inclusion signed written informed consent given by the patient no corresponding to the inclusion criteria another malignant tumour treated for curative purposes during the past 5 years excepted basocellular skin carcinoma or in situ uterine cervix cancer allergy to the active substance or one of the excipients in the study drugs pregnancy or breastfeeding any other concommitant treatment, immunotherapy or hormonal therapy history of abdominal or chest radiotherapy any evolving disorder which is not under control (liver failure, kidney failure, respiratory failure, evolving heart failure or myocardial necrosis during the past 6 months) patients who cannot be regularly monitored</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Signet ring cell</keyword>
	<keyword>gastric adenocarcinoma</keyword>
	<keyword>peri-operative chemotherapy</keyword>
	<keyword>surgery</keyword>
</DOC>